Regarding Mannitol for increased ICP, which statement is incorrect?

Mannitol is an osmotic diuretic commonly used in the management of increased intracranial pressure (ICP). It works primarily by creating an osmotic gradient that draws water out of the brain tissue and into the bloodstream, effectively reducing cerebral edema. This mechanism is essential for lowering ICP.

When considering the statement that Mannitol will cause water and electrolyte reabsorption in the renal tubules, it's critical to understand that Mannitol actually promotes diuresis rather than reabsorption. By increasing the osmolarity of the filtrate in the renal tubules, Mannitol inhibits the reabsorption of water and electrolytes, leading to increased urine output. Therefore, this statement does not accurately reflect the pharmacodynamic properties of Mannitol.

Monitoring for fluid volume overload or depletion is important while administering Mannitol because the osmotic effect can lead to substantial fluid shifts that may affect blood volume and pressure. The use of Mannitol in patients with anuria is contraindicated because it may exacerbate renal failure situations by further preventing the kidneys from excreting excess fluid, potentially leading to complications. Thus, understanding the specific pharmacological effects of Mannitol clarifies why the statement about water and electrolyte reabsorption is indeed incorrect.